CD44 showed comparable sensitivity and specificity rates as proteinuria (sensitivity and specificity rates of 88.89% and 100.00% respectively) and renal SLEDAI-2K scores (sensitivity and specificity rates of 84.62% and 87.80% respectively) in distinguishing between patients with active LN and those in remission. This evidence concerns the gene CD44 and lobular neoplasia.